vimarsana.com

Inzen Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

Astellas pharmaImmatics incyteCrown bioscienceJason lukeImmunocore incytePembrolizumab keytrudaTrex bioCodiak biosciencesBristol myers squibbHillman cancer centerCancer immunotherapeutic centerGilead sciencesImmunotherapy programCstone pharmaceuticalsTizona therapeutics incDivision of hematology oncology

Flagship Pioneering Unveils Sonata Therapeutics to Harness Cellular Microenvironments for the Treatment of Serious Diseases

/PRNewswire/ Flagship Pioneering, the bioplatform innovation company, today announced the unveiling of a new company – Sonata Therapeutics – to develop.

Doug coleJason bracoVolker herrmannPearl huangNoubar afeyanLifesci communicationsManaging partnerInzen therapeuticsCygnal therapeuticsFlagship pioneering founderInzen chief executive officerFormer cygnalFlagship pioneeringSonata therapeuticFlagship labsAxcella therapeutics

Flagship merges two of its biotechs to form cellular microenvironment-focused Sonata

Sonata Therapeutics is developing drugs that reprogram cellular microenvironments to send signals intended to have curative effects. Cancer is the initial focus of the biotech, which Flagship Pioneering formed by combining two of its preclinical portfolio companies.

United kingdomUnited statesSenda biosciencesVolker herrmannPearl huangNoubar afeyanSonata therapeuticsFlagship pioneering backedCygnal therapeuticsInzen therapeuticsKintai therapeuticsRepertoire medicinesTorque therapeuticsCogen immuneWeight lossMedical devices

Flagship Pioneering Unveils Sonata Therapeutics to Harness Cellular Microenvironments for the Treatment of Serious Diseases

Platform insights are generating a growing pipeline of small molecule drugs and genetic therapeuticsCompany will initially focus on oncology, fibr.

Doug coleJason bracoVolker herrmannPearl huangNoubar afeyanLifesci communicationsSonata therapeuticsManaging partnerInzen therapeuticsCygnal therapeuticsFlagship pioneering founderInzen chief executive officerFormer cygnalFlagship pioneeringSonata therapeuticFlagship labs

Reaction Biology Announces Expansion of Executive Leadership Team with Key Appointments in Commercial and Human Resources Functions

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Glasgow cityUnited kingdomLindsay roccoJohnh johnsonStrongbridge biopharmaAlan findlaterAsia pacificEmily doyleCorporate development at charles river laboratoriesUniversity of strathclydeInstitute of marketingCavium incGlobal human resources at globus medical incElixir health public relationsLasalle universityResearch models

vimarsana © 2020. All Rights Reserved.